Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Uppsala, Sweden, May 28, 2025. Dicot Pharma can today announce that the latest studies on the mechanism of action of their candidate drug LIB-01 show that it affects nerves and vascular structures which interact in creating penile erection. The results can also explain LIB-01's long-lasting effect and emphasize the differentiation to current potency drugs.
Dicot Pharma has previously announced that the mechanism of action of the drug candidate LIB-01 differs from currently used potency drugs and thus has the potential to change the paradigm of erectile dysfunction management. The company is characterizing the mechanism of action of LIB-01 and now new results show that LIB-01 affects underlying structures that play a central role in penile erection.
A penile erection is a vascular event that occurs in response to sexual stimulation. A dramatic increase in arterial inflow to the penis is essential for an erection and it must be accompanied by a relaxation of the erectile tissue of the penis for the cavernous bodies to fill with blood. Everything is under neural command. By analyzing gene expressions in anatomical structures involved in penile erection, Dicot Pharma has found that LIB-01 affects the nervous and vascular structures that are involved in these processes.
These findings differentiate LIB-01 from today's oral potency drugs, the PDE5 inhibitors, which act within the erectile tissue facilitating blood trapping within the penis and thus depend on a sufficient arterial inflow. The fact that LIB-01 affects the underlying structures that control the inflow thus supports the company's goal of also being able to treat men who are not currently helped by PDE5 inhibitors.
The change in gene expression may also explain the long-lasting effect of LIB-01 on erectile function. Gene expression is a naturally occurring process whereby information from genes is transferred to the cell's structures and functions, which is crucial for various biological functions, and the effects can be long-lasting.
Dicot Pharma is now continuing to characterize the mechanism of action, including studies of specific processes in the body that could cause these gene expression changes.
"The fact that LIB-01 acts on structures that control penile erection, rather than in the erectile tissue, is a very important distinction. In addition, we have now found an explanatory model for the long duration of action. From a scientific perspective, these research findings are very interesting, and I look forward to continuing to unfold the mechanism of action", says Dicot Pharma's CSO Charlotta Gauffin.
"There is no potency drug today that works in this way. It underlines our potential to revolutionize the market and offer a completely new treatment that can help many more people", comments Dicot Pharma's CEO Elin Trampe.